Better late than early: FDG-PET imaging in metastatic renal cell carcinoma

Clinical Cancer Research

Volumn 17, Issue 18, 2011, Pages 5841-5843

  Harrison, Michael R ^a,b   George, Daniel J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SUNITINIB;

ARTICLE; CANCER CELL; CELL METABOLISM; DRUG UPTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TUMOR REGRESSION;

CARCINOMA, RENAL CELL; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80052867881     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1768     Document Type: Article

References (12)

1. Kayani I, Avril N, Bomani J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011;17:6021-8.
2. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002;9:15-8.
3. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009;24:137-44.
4. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011;23:339-43.
5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
7. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009;9:82.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
9. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
10. 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009;27:439-45.
11. Liu G, Jeraj R, Perlman S, Vanderhoek M, Kolesar J, Eickhoff J, et al. Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib. J Clin Oncol 2008;26:3515.
12. Bjarnason GA, Williams R, Hudson JM, Bailey C, Lee CR, Lloyd BA, et al. Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2011;29:4627.